Physician profile
Asad Ismail
NPI 1144227026
$9,994.56
in general payments reported to CMS, 2019-2025
39 companies · $1,986 in 2025
The $1,986 reported for 2025 was more than what 85% of Addiction Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $851 · 2021: $2,036 · 2022: $1,281 · 2023: $1,363 · 2024: $2,011 · 2025: $1,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,167 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,167.19 |
| Education | $192.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,231.12 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $935.36 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $838.68 | 2020-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $695.47 | 2021-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $655.58 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Indivior INC. | $650.04 | 2019-2025 | Sublocade, Perseris |
| Janssen Pharmaceuticals, INC | $595.44 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $442.35 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Allergan, INC. | $385.31 | 2019-2020 | |
| Lundbeck LLC | $268.57 | 2019-2025 | Rexulti |
| Amgen INC. | $248.48 | 2020-2022 | |
| Axsome Therapeutics, INC. | $221.94 | 2022-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $214.06 | 2022-2025 | Ingrezza |
| Uswm, LLC | $197.03 | 2022-2024 | Lucemyra, Zimhi |
| E.R. Squibb & Sons, L.L.C. | $195.84 | 2024-2025 | Cobenfy |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asad Ismail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.